- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04520672
Circulating Tumor Cells (CTC) in Cancer
February 19, 2024 updated by: University Hospital, Basel, Switzerland
This observational study with circulating tumor cells (CTC) count, isolation and analysis at several time points during disease progression is to investigate the role and biology of CTCs and clusters of CTCs in different cancer types.
It also evaluates the role of CTCs as biomarkers, and aims at the identification of key signaling networks that are active in CTCs.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
3000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Marcus Vetter, PD Dr. med.
- Phone Number: +41 61 925 27 15
- Email: marcus.vetter@ksbl.ch
Study Contact Backup
- Name: Nicola Aceto, Prof. Dr. med.
- Phone Number: +41 44 633 40 23
- Email: nicola.aceto@biol.ethz.ch
Study Locations
-
-
-
Basel, Switzerland, 4031
- Recruiting
- University Hospital Basel
-
Contact:
- Christian Kurzeder, PD Dr. med.
- Phone Number: +41 61 265 2525
- Email: christian.kurzeder@usb.ch
-
Principal Investigator:
- Christian Kurzeder, PD Dr. med.
-
Sub-Investigator:
- Fabienne Schwab, Dr. med
-
Sub-Investigator:
- Viola Heinzelmann-Schwarz, Prof. Dr. med
-
Sub-Investigator:
- Christoph Rochlitz, Prof. Dr. med.
-
Sub-Investigator:
- Julia Landin, Dr. med.
-
Sub-Investigator:
- Alfred Zippelius, Prof. Dr. med.
-
Sub-Investigator:
- Heinz Läubli, PD Dr. med.
-
Sub-Investigator:
- Walter Weber, Prof. Dr. med.
-
Sub-Investigator:
- Dörthe Schaefer-Rohr, Dr. med.
-
Sub-Investigator:
- Homen Begovic, Dr. med.
-
Sub-Investigator:
- Christine Wenk, Dr. med.
-
Sub-Investigator:
- Daniel Steffens, Dr. med.
-
Sub-Investigator:
- Anna Schollbach, Dr. med.
-
Sub-Investigator:
- Ilker Acemoglu, Dr. med.
-
Sub-Investigator:
- Simone Münst, PD Dr. med.
-
Sub-Investigator:
- Tatjana Vlajnic, Dr. med.
-
Liestal, Switzerland, 4410
- Recruiting
- Department Oncology, Haematology & Immuntherapy, Kantonsspital Baselland
-
Contact:
- Marcus Vetter, PD Dr. med.
- Phone Number: +41 61 925 27 15
- Email: marcus.vetter@ksbl.ch
-
Sub-Investigator:
- Robert Rosenberg, Prof. Dr. med.
-
Sub-Investigator:
- Emanuel Burri, PD Dr. med.
-
Principal Investigator:
- Marcus Vetter, PD Dr. med.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
adult patients (> 18 years) with a cancer diagnosis
Description
Inclusion Criteria:
- Adult cancer patients
- All patients with histology-based proved diagnosis of cancer, all stages and subtypes can be included. Precancerous lesions cannot be included.
- All patients with the diagnosis of a solid tumor including adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, sarcoma
- Written pathology report must be available.
- Written informed consent.
Exclusion Criteria:
- No written informed consent.
- No proved diagnosis of malignancy by pathology report.
- Patients with the diagnosis of blood cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS) in heterogeneous cancer population
Time Frame: Screening (Visit 1) until the date of death (assessed up to 240 months)
|
overall survival (OS) in heterogeneous cancer population
|
Screening (Visit 1) until the date of death (assessed up to 240 months)
|
Change in total number of isolated CTCs
Time Frame: Through study completion, an average of 20 years
|
Change in total number of isolated CTCs
|
Through study completion, an average of 20 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS)
Time Frame: Through study completion, an average of 20 years
|
progression free survival (PFS) in the different cancer cohorts with different treatment regimes
|
Through study completion, an average of 20 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in circulating tumor DNA (ctDNA) from blood samples
Time Frame: Through study completion, an average of 20 years
|
Change in circulating tumor DNA (ctDNA) from blood samples
|
Through study completion, an average of 20 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Marcus Vetter, PD Dr. med., Kantonsspital Baselland, Liestal
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2020
Primary Completion (Estimated)
August 1, 2030
Study Completion (Estimated)
August 1, 2030
Study Registration Dates
First Submitted
August 5, 2020
First Submitted That Met QC Criteria
August 17, 2020
First Posted (Actual)
August 20, 2020
Study Record Updates
Last Update Posted (Actual)
February 20, 2024
Last Update Submitted That Met QC Criteria
February 19, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-00014; me19Vetter
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on Blood samples
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Centre Hospitalier Universitaire DijonCompletedPrimary Immune Thrombocytopenia (ITP)France
-
Institut BergoniéUnknown
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownPaediatric MalignanciesFrance
-
Centre Georges Francois LeclercCompleted
-
Centre Hospitalier Universitaire de NīmesCompletedHenoch Schönlein PurpuraFrance
-
Centre Hospitalier Universitaire DijonCompleted
-
Assistance Publique Hopitaux De MarseilleRecruitingPlastic SurgeriesFrance
-
University Hospital, BordeauxRecruitingSystemic Sclerosis | SclerodermaFrance
-
Centre Hospitalier Universitaire, AmiensCompleted